These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 2590554)

  • 1. A rapid, quantitative bioassay based on the human immunodeficiency virus trans-activator.
    Hasler JM; Weighous TF; Pitts TW; Evans DB; Sharma SK; Tarpley WG
    AIDS Res Hum Retroviruses; 1989 Oct; 5(5):507-16. PubMed ID: 2590554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretion of enzymatically active human renin from mammalian cells using an avian retroviral vector.
    Weighous TF; Cornette JC; Sharma SK; Tarpley WG
    Gene; 1986; 45(2):121-9. PubMed ID: 3026901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide.
    Jiang A; Fisher H; Pomerantz RJ; Dornburg R
    Hum Gene Ther; 1999 Nov; 10(16):2627-36. PubMed ID: 10566890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
    Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
    Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal and Tat-transactivated expression from the human immunodeficiency virus type 1 long terminal repeat in human placental trophoblast rules out promoter-enhancer activation as the partial block to viral replication.
    Zachar V; Ebbesen P; Thomas RA; Zacharova V; Goustin AS
    J Gen Virol; 1994 Jun; 75 ( Pt 6)():1461-8. PubMed ID: 8207411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
    Robinson D; Elliott JF; Chang LJ
    Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.
    Kolson DL; Collman R; Hrin R; Balliet JW; Laughlin M; McGann KA; Debouck C; Gonzalez-Scarano F
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():1927-34. PubMed ID: 8046394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication.
    Accolla RS; Mazza S; De Lerma Barbaro A; De Maria A; Tosi G
    Eur J Immunol; 2002 Oct; 32(10):2783-91. PubMed ID: 12355430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and expression of the equine infectious anemia virus transcriptional trans-activator (tat).
    Derse D; Dorn P; DaSilva L; Martarano L
    Dev Biol Stand; 1990; 72():39-48. PubMed ID: 2178129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
    Kashanchi F; Sadaie MR; Brady JN
    Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B.
    Negrini M; Rimessi P; Sabbioni S; Caputo A; Balboni PG; Gualandri R; Manservigi R; Grossi MP; Barbanti-Brodano G
    Biotechniques; 1991 Mar; 10(3):344-53. PubMed ID: 1829615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators.
    Madore SJ; Cullen BR
    Virology; 1995 Feb; 206(2):1150-4. PubMed ID: 7856090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine augmentation of HIV-1 LTR-driven gene expression in neural cells.
    Swingler S; Easton A; Morris A
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):487-93. PubMed ID: 1599755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 tat gene enhances human cytomegalovirus gene expression and viral replication.
    Ho WZ; Ayyavoo V; Srinivasan A; Stinski MF; Plotkin SA; Gönczöl E
    AIDS Res Hum Retroviruses; 1991 Aug; 7(8):689-95. PubMed ID: 1657075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of vaccinia virus vectors to study the synthesis, intracellular localization, and action of the human immunodeficiency virus trans-activator protein.
    Falkner FG; Fuerst TR; Moss B
    Virology; 1988 Jun; 164(2):450-7. PubMed ID: 2835862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.
    Kao SY; Calman AF; Luciw PA; Peterlin BM
    Nature; 1987 Dec 3-9; 330(6147):489-93. PubMed ID: 2825027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein.
    Dis Markers; 1990; 8(1):34-5. PubMed ID: 2178856
    [No Abstract]   [Full Text] [Related]  

  • 19. The CAEV tat gene trans-activates the viral LTR and is necessary for efficient viral replication.
    Saltarelli MJ; Schoborg R; Gdovin SL; Clements JE
    Virology; 1993 Nov; 197(1):35-44. PubMed ID: 8212571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.
    Modesti N; Garcia J; Debouck C; Peterlin M; Gaynor R
    New Biol; 1991 Aug; 3(8):759-68. PubMed ID: 1931822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.